Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 72.6% in May

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large decline in short interest in May. As of May 29th, there was short interest totaling 30,887 shares, a decline of 72.6% from the May 14th total of 112,539 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 560,221 shares, the days-to-cover ratio is currently 0.1 days.

Oncotelic Therapeutics Price Performance

OTLC stock traded down $0.00 during midday trading on Friday, hitting $0.05. 244,391 shares of the stock were exchanged, compared to its average volume of 227,813. The stock’s 50-day moving average price is $0.04 and its 200-day moving average price is $0.06. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.11 and a current ratio of 0.11. The stock has a market cap of $21.38 million, a price-to-earnings ratio of 0.08 and a beta of -0.34. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.11.

Oncotelic Therapeutics (OTCMKTS:OTLC) last announced its quarterly earnings data on Wednesday, April 15th. The company reported $0.59 earnings per share for the quarter.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.